Thio et al., 2011 - Google Patents
Immunoglobulin free light chains: new insights in mast cell activation and immunologyThio et al., 2011
View PDF- Document ID
- 11758687411842114475
- Author
- Thio M
- et al.
- Publication year
External Links
Snippet
In this thesis, several studies are described that elaborate on the biological properties of immunoglobulin free light chains (Ig-fLC) related to the activation of mast cells and effects on other cells. Mast cell degranulation through Ig-fLC requires two events. At first, mast cell …
- 210000000138 Mast Cells 0 title abstract description 234
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sicard et al. | Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients | |
| Nakamura et al. | Cell contact–dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface–bound transforming growth factor β | |
| JP3007977B2 (en) | Method of inducing antigen-specific T cell tolerance | |
| JP5693127B2 (en) | Regulation of NKG2D | |
| JP2009034108A (en) | Therapeutic binding molecule | |
| Wu et al. | Suppression of murine SLE by oral anti-CD3: inducible CD4+ CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells | |
| Wang et al. | Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells | |
| RU2598719C2 (en) | Drugs for treating diseases | |
| JP2000508226A (en) | Method for detecting, identifying, isolating, and selectively labeling and targeting TH1 lymphocytes with LAG-3 protein | |
| CN117887744A (en) | Compositions and methods for treating cancer using chimeric antigen receptors targeting claudin 18.2 | |
| Camara et al. | CD8+ T cell help is required for efficient induction of EAE in Lewis rats | |
| CN105886466A (en) | Methods and compositions for modulating voltage-gated calcium channel function | |
| EP1404362B1 (en) | Signal-1/signal-2 bifunctional peptide inhibitors | |
| US20210325372A1 (en) | Method to assess car functionality | |
| JPWO2005094886A1 (en) | Regulatory T cell differentiation induction / proliferation method with GPI anchor protein agonist and pharmaceutical composition therefor | |
| Thio | Immunoglobulin free light chains: new insights in mast cell activation and immunology | |
| CN116963746A (en) | Methods to selectively target CD6-high cells and reduce the activity of TEFF cells | |
| JP5616782B2 (en) | Antibody with immune enhancement function | |
| BRPI0616438A2 (en) | protein, polynucleotide, antibody against a secretory or membrane protein, or a functional fragment thereof, hybridoma, therapeutic agent for an autoimmune disease, agent for inhibiting t-cell adhesion, and method for screening for a substance | |
| ES2360373T3 (en) | CD86 AND CD80 RECEIVER COMPETITION TESTS. | |
| KR20250113410A (en) | Patient selection and treatment monitoring for autoimmune disorders | |
| KR20240045239A (en) | Manufacturing method of personalized cancer immunotherapy | |
| Prati | Evaluation of strategies to suppress IgE mediated hypersensitivity reactions | |
| Reichardt et al. | CD8+ T cell help is required for efficient induction of EAE in Lewis rats | |
| JP2022515226A (en) | Detection / processing configuration and method |